Ro 48-8071

• Description :

  Ro 48-8071 is an inhibitor of OSC (Oxidosqualene cyclase) with IC50 of appr 6.5 nM.

• UNSPSC :

  12352005

• Hazard Statement :

  H302, H315, H319, H335

• Target :

  Others

• Type :

  Reference compound

• Related Pathways :

  Others

• Applications :

  Cancer-programmed cell death

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/Ro-48-8071-fumarate.html

• Purity :

  99.13

• Solubility :

  DMSO : ≥ 55 mg/mL|H2O : 100 mg/mL (ultrasonic)

• Smiles :

  O=C(C1=CC=C(Br)C=C1)C2=CC=C(OCCCCCCN(C)CC=C)C=C2F.O=C(O)/C=C/C(O)=O

• Molecular Formula :

  C27H31BrFNO6

• Molecular Weight :

  564.44

• Precautions :

  H302, H315, H319, H335

• References & Citations :

  [1]Morand OH, et al. Ro 48-8.071, a new 2,3-oxidosqualene:lanosterol cyclase inhibitor lowering plasma cholesterol in hamsters, squirrel monkeys, and minipigs: comparison to simvastatin. J Lipid Res. 1997 Feb;38 (2) :373-90.|[2]Liang Y, et al. Cholesterol biosynthesis inhibitor RO 48-8071 suppresses growth of hormone-dependent and castration-resistant prostate cancer cells. Onco Targets Ther. 2016 May 30;9:3223-32|[3]Liang Y, et al. Cholesterol biosynthesis inhibitors as potent novel anti-cancer agents: suppression of hormone-dependent breast cancer by the oxidosqualene cyclase inhibitor RO 48-8071. Breast Cancer Res Treat. 2014 Jul;146 (1) :51-62.|[4]Chuang JC, et al. Sustained and selective suppression of intestinal cholesterol synthesis by Ro 48-8071, an inhibitor of 2,3-oxidosqualene:lanosterol cyclase, in the BALB/c mouse. Biochem Pharmacol. 2014 Apr 1;88 (3) :351-63.

• Shipping Conditions :

  Room Temperature

• Storage Conditions :

  4°C (Powder, sealed storage, away from moisture)

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Citation 01 :

  Cancer Res Commun. 2024 Sep 1;4 (9) :2427-2443.|Cell Death Dis. 2021 May 13;12 (5) :482.|Cell Death Discov. 2025 Feb 8;11 (1) :55.|Cell Rep. 2022 Dec 13;41 (11) :111827.|Immunomedicine. 2022 Dec;2 (2) :e1041.|Mol Med Rep. 2021 Dec;24 (6) :828.|Neoplasia. 2025 Oct 27:70:101243.|ACS Synth Biol. 2023 May 19;12 (5) :1408-1414.|Cancer Cell. 2023 Jul 10;41 (7) :1276-1293.e11.|Mol Cell. 2021 Jul 1;81 (13) :2736-2751.e8.|Nat Commun. 2023 Jul 17;14 (1) :4267.|Oncotarget. 2017 Feb 28;8 (9) :14860-14875.|Sci China Life Sci. 2022 Feb;65 (2) :341-361.

• CAS Number :

  [189197-69-1]